Abstract
A first patient has been dosed in a Phase 1 clinical study (NCT06440005) with AGX101, a novel TM4SF1-directed Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapy for the treatment of solid tumors. AGX101, which is being developed by privately held biotech startup Angiex, is based on a new, groundbreaking ADC technology platform with a unique mechanisms of action.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
